A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 247 participants.

Also called NCT03751657

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 247 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03751657
  • EudraCT 2018-000322-63
Other papers using this trial's data
  • Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment The New England journal of medicine, 2020-11-26 DOI, PubMed 32960514

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Greece, Poland, Slovakia, Slovenia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03751657. Randomized; quadruple masking; primary purpose treatment. Start 2018-11-29 (actual); primary completion 2019-12-16 (actual). Results posted on 2021-02-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin icodec
Intervention (Drug)
Placebo (insulin 287)
Intervention (Drug)
Metformin
Intervention (Drug)
Dipeptidyl peptidase-4 inhibitors
Intervention (Drug)
Insulin glargine
Intervention (Drug)
Placebo (insulin glargine)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03751657
Content hash
8f0e8b9d21d697619fb1e305e30319294d11346bef4b7d5f9ef9212e5c9bee5b